Specialties
Theranostics
Cancer is personal. Its treatment should be too. GE HealthCare’s complete portfolio of Theranostics-enabling solutions is designed specifically for this new era in cancer care. Join us on this journey to transform the approach to cancer discovery, diagnosis, and treatment. Because the future of medicine is here—and it’s personal. Are you ready?
SNMMI 2023 | June 24-27, 2023
SNMMI 2023 | June 24-27, 2023
SNMMI 2023 | June 24-27, 2023
DISCOVERY
GE HealthCare’s PET Radiopharmacy drives innovation
Partnering with leading clinical,
academic, pharmaceutical, and
research organizations to
innovate, streamline production
and distribution, and
commercialize new
radiopharmaceuticals and
solutions.
DIAGNOSIS
GE is pioneering the solutions that enable unparalleled sensitivity and diagnostic confidence.
Our dedicated portfolio of Theranostics-focused diagnostic imaging solutions was engineered specifically to meet clinicians’ needs—and those of their patients— today and in the future.
THERAPY IMAGING AND MONITORING
Cancer is personal.
Its treatment should be too.
GE HealthCare is shaping the future of Theranostics today with precise imaging and monitoring solutions and innovations of treatment response.
DIGITAL AI
Digital Accuracy for Precision Health
Bringing you leading-edge applications for visualization, quantitation, and dosimetry.
DIGITAL AI PRODUCTS
There is so much data available across molecular imaging today. There are so many connection opportunities and loops to close. GE can help.
Q.Thera AI⁵
Q.Volumetrix AI
Q.Liver
Practical considerations needed in establishing a Theranostics program from SNMMI 2022: We really have a long way to go to meet the need of the market right now let alone what is coming in the future.
Medhat M. Osman, MD, PhD, ScM
Chair of Nuclear Medicine, Saint Louis UniversityINNOVATIONS
Only GE HealthCare —for wherever you are on your Theranostics journey
The future is happening now. One-size-fits-all just doesn’t work anymore. At GE HealthCare, we’re personalizing the path to precision healthCare. Join us, as we work toward enabling better outcomes. Join us, as we provide hope.
Community Hospitals and Imaging Centers
Referring Physicians
Patients
1 Omni Legend 32cm as compared to Discovery MI 25cm. Measurements follow NEMA NU 2-2018.
2 Omni Legend compared to Discovery MI. As demonstrated in phantom testing.
3 Source: MEDRaysintell2021
4 Omni Legend compared to Discovery MI. As demonstrated in phantom testing.
5 Q.Thera AI is 510(k) pending at the US FDA. Not cleared for sales in the United States.
6 Compared to using Xeleris’s Dosimetry Toolkit with dose calculations done with external software. As demonstrated in bench test using 5 SPECT-CT cases. The bench test covered the workflowfrom data loading to image processing and dose calculation. Results may vary.
7 Compared to using Xeleris 4 DR Q.Volumetrix MI with manual or external software dose calculation. As demonstrated in an evaluation at 2 sites consisting of 15 SPECT-CT cases and 2 physicians, where each case was processed by 1 of the 2 physicians. Results may vary.
8 Compared to using Xeleris 4 DR Q.Volumetrix with manual or external software dose calculation. As demonstrated in bench test using 5 SPECT-CT cases. The bench test covered the workflow from data loading to dose calculation using user pre-defined formulas. Results may vary.
9 https://www.cancer.org/cancer/prostate-cancer/about/key-statistics.html#:~:text=Other%20than%20skin%20cancer%2C%20prostate,34%2C500%20deaths%20from%20prostate%20cancer
2 Omni Legend compared to Discovery MI. As demonstrated in phantom testing.
3 Source: MEDRaysintell2021
4 Omni Legend compared to Discovery MI. As demonstrated in phantom testing.
5 Q.Thera AI is 510(k) pending at the US FDA. Not cleared for sales in the United States.
6 Compared to using Xeleris’s Dosimetry Toolkit with dose calculations done with external software. As demonstrated in bench test using 5 SPECT-CT cases. The bench test covered the workflowfrom data loading to image processing and dose calculation. Results may vary.
7 Compared to using Xeleris 4 DR Q.Volumetrix MI with manual or external software dose calculation. As demonstrated in an evaluation at 2 sites consisting of 15 SPECT-CT cases and 2 physicians, where each case was processed by 1 of the 2 physicians. Results may vary.
8 Compared to using Xeleris 4 DR Q.Volumetrix with manual or external software dose calculation. As demonstrated in bench test using 5 SPECT-CT cases. The bench test covered the workflow from data loading to dose calculation using user pre-defined formulas. Results may vary.
9 https://www.cancer.org/cancer/prostate-cancer/about/key-statistics.html#:~:text=Other%20than%20skin%20cancer%2C%20prostate,34%2C500%20deaths%20from%20prostate%20cancer